


<b>FORM PTO-1449</b> To: U.S. Department of Commerce Patent and Trademark Office				Atty. Dkt. No.		M#		Client Ref.	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <div style="text-align: center; margin-top: 20px;">  </div>				056291-5019		Applicant: HENNEQUIN et al.  Appln. No.: 09/913,020 Filing Date: May 6, 2002 Examiner: Truong, T.      Group Art Unit: 1624			
Date: July 14, 2004      Page 1 of 1									
<b>U.S. PATENT DOCUMENTS</b>									
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)			
RR	AR 2002/0177601 A1	11/2002	Himmelsbach et al.						
	BR								
	CR								
	DR								
	ER								
	FR								
	GR								
	HR								
	IR								
	JR								
<b>FOREIGN PATENT DOCUMENTS</b>									
		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
RR	KR	00/44728	08/2000	WIPO	Kath et al.				
RR	LR	00/55141	09/2000	WIPO	Himmelsbach et al.				
RR	MR	01/29025 A2	04/2001	WIPO	Arrington et al.				
	NR								
	OR								
	PR								
	QR								
	RR								
<b>OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)</b>									
	SR								
	TR								
	UR								
	VR								
Examiner <i>R. R. R.</i>					Date Considered: 7-1-04				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.									

518 Rec'd PCT/PTO 09 AUG 2001

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

Atty.  
Dkt. No.

M#

Client Ref.

282705

Z70495/UST

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: HENNEQUIN, Laurent et al

Appln. No.: New Application

09/913020

Filing Date: August 9, 2001

Date: August 9, 2001

Page 1 of 1

Examiner: unassigned

Group Art Unit: unassigned

## U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						

## FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		Abstract		Readily Available	
							Enclosed	No	Enclose	No
on quent ing	DR	WO 96 29301	9/1996	WIPO						
	ER	WO 95 15758	6/1995	WIPO						
	FR	602 851	6/1994	EP						
	GR	WO 97 42187	11/1997	WIPO						
	HR	WO 99 10340	3/1999	WIPO						
	IR	WO 97 22596	6/1997	WIPO						
	JR									
	KR									
	LR									
	MR									

## OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.):

NR	HENNEQUIN et al: "Design and Structure Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors", J.MED.CHEM.(JMCMAR,0022623); 1999; VOL. 42 (26); PP 5369-389, XP000197180 AstraZeneca Zeneca Pharma Centre de Recherches Z.I. La Pompelle; Reims; 51689; FR			
OR	BRIDGES et al: "Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines" BIOORG.MED.CHEM (BMECEP, 09680896); 1995; VOL. 3 (12)PP 1651-6, XP002134974 Parke-Davis Pharmaceutical Research Division; Ann Arbor; 48106; MI; USA (US)			
PR	GIBSON et al: "Epidermal growth factor receptor tyrosine kinase: structure activity relationships and antitumor activity of novel quinazolines" BIOORG.MED.CHEM LETT. (BMCLet, 0960894X); 1997; VOL. 7 (21)PP 2723-2728, XP002134975 Zeneca Pharmaceuticals; Research Dep. Cancer, Metabolism and Endocrine; Alderley Park, Macclesfield, Cheshire, SK10 4TG; UK (GB)			
QR				
RR				
SR				

Examiner

Date Considered:

9-1-01

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.